Literature DB >> 26840970

Changes in Nonosteoporotic Bone Density and Subsequent Fractures in Women.

Alfred K Pfister1, Christine A Welch1, Molly John1, Mary K Emmett1.   

Abstract

OBJECTIVES: Osteopenia is considerably more common than osteoporosis and accounts for most of the fracture burden in women older than 50 years. It is uncertain when to initiate treatment in osteopenia. We sought to determine in women with osteopenia what effect transitioning to lower categories had on subsequent fracturing.
METHODS: We surveyed 1150 women from office-based practices who had initial normal or osteopenic bone mineral densities (BMDs) and who were retested after 5.75 years. We classified categories related to baseline T scores as follows: normal (>-1.0), mild osteopenia (-1.0 to -1.49), moderate osteopenia (-1.5 to -1.99), and severe osteopenia (-2.0 to -2.49). We determined during a 9.6-year follow-up period the fracture occurrence in those who maintained their initial category status or transitioned into lower categories.
RESULTS: Transitioning to lower categories was not significantly different among baseline osteopenic categories but significantly more than normal baseline BMDs. Total fractures, individuals fracturing, and major fractures were significantly more, with baseline T scores of ≤-1.5 (<0.001). Although only 10.2% transitioned to osteoporosis, 90.5% of these transitions occurred with baseline T scores ≤-1.5 and accounted for significantly more fractures than baseline T scores of >-1.5.
CONCLUSIONS: Most subsequent fractures and transitions to osteoporosis occurred with baseline T scores ≤-1.5. Clinical risk factors need to be used to determine at what T score threshold treatment would be cost effective.

Entities:  

Mesh:

Year:  2016        PMID: 26840970      PMCID: PMC4979224          DOI: 10.14423/SMJ.0000000000000410

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  33 in total

Review 1.  FRAX and its applications to clinical practice.

Authors:  John A Kanis; Anders Oden; Helena Johansson; Fredrik Borgström; Oskar Ström; Eugene McCloskey
Journal:  Bone       Date:  2009-02-03       Impact factor: 4.398

Review 2.  Indications of DXA in women younger than 65 yr and men younger than 70 yr: the 2013 Official Positions.

Authors:  Alan O Malabanan; Harold N Rosen; Tamara J Vokes; Chad L Deal; Jimmy D Alele; Thomas P Olenginski; John T Schousboe
Journal:  J Clin Densitom       Date:  2013-09-20       Impact factor: 2.617

3.  Cortical bone resorption rate in elderly persons: estimates from long-term in vivo measurements of (90)Sr in the skeleton.

Authors:  N B Shagina; E I Tolstykh; M O Degteva; L R Anspaugh; B A Napier
Journal:  Arch Gerontol Geriatr       Date:  2011-08-25       Impact factor: 3.250

4.  Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.

Authors:  Jane A Cauley; John Robbins; Zhao Chen; Steven R Cummings; Rebecca D Jackson; Andrea Z LaCroix; Meryl LeBoff; Cora E Lewis; Joan McGowan; Joan Neuner; Mary Pettinger; Marcia L Stefanick; Jean Wactawski-Wende; Nelson B Watts
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

5.  Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial.

Authors:  John A Kanis; Olof Johnell; Dennis M Black; Robert W Downs; Somnath Sarkar; Thomas Fuerst; Roberta J Secrest; Imre Pavo
Journal:  Bone       Date:  2003-09       Impact factor: 4.398

6.  Trabecular structure quantified with the MRI-based virtual bone biopsy in postmenopausal women contributes to vertebral deformity burden independent of areal vertebral BMD.

Authors:  Glenn A Ladinsky; Branimir Vasilic; Andra M Popescu; Michael Wald; Babette S Zemel; Peter J Snyder; Louise Loh; Hee Kwon Song; Punam K Saha; Alexander C Wright; Felix W Wehrli
Journal:  J Bone Miner Res       Date:  2008-01       Impact factor: 6.741

7.  Cortical porosity identifies women with osteopenia at increased risk for forearm fractures.

Authors:  Yohann Bala; Roger Zebaze; Ali Ghasem-Zadeh; Elizabeth J Atkinson; Sandra Iuliano; James M Peterson; Shreyasee Amin; Åshild Bjørnerem; L Joseph Melton; Helena Johansson; John A Kanis; Sundeep Khosla; Ego Seeman
Journal:  J Bone Miner Res       Date:  2014-06       Impact factor: 6.741

8.  Repeat low-trauma fractures occur frequently among men and women who have osteopenic BMD.

Authors:  Lisa Langsetmo; David Goltzman; Christopher S Kovacs; Jonathan D Adachi; David A Hanley; Nancy Kreiger; Robert Josse; Alexandra Papaioannou; Wojciech P Olszynski; Sophie A Jamal
Journal:  J Bone Miner Res       Date:  2009-09       Impact factor: 6.741

Review 9.  Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry.

Authors:  Sanford Baim; Charles R Wilson; E Michael Lewiecki; Marjorie M Luckey; Robert W Downs; Brian C Lentle
Journal:  J Clin Densitom       Date:  2005       Impact factor: 2.963

10.  Abnormal microarchitecture and reduced stiffness at the radius and tibia in postmenopausal women with fractures.

Authors:  Emily M Stein; X Sherry Liu; Thomas L Nickolas; Adi Cohen; Valerie Thomas; Donald J McMahon; Chiyuan Zhang; Perry T Yin; Felicia Cosman; Jeri Nieves; X Edward Guo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2010-06-18       Impact factor: 6.741

View more
  1 in total

1.  Melatonin-micronutrients Osteopenia Treatment Study (MOTS): a translational study assessing melatonin, strontium (citrate), vitamin D3 and vitamin K2 (MK7) on bone density, bone marker turnover and health related quality of life in postmenopausal osteopenic women following a one-year double-blind RCT and on osteoblast-osteoclast co-cultures.

Authors:  Sifat Maria; Mark H Swanson; Larry T Enderby; Frank D'Amico; Brianna Enderby; Rebekah M Samsonraj; Amel Dudakovic; Andre J van Wijnen; Paula A Witt-Enderby
Journal:  Aging (Albany NY)       Date:  2017-01-26       Impact factor: 5.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.